Tianeptine 

Brand Name: Stablon

Tianeptine (Stablon, Coaxil, Tatinol), is described as a selective serotonin reuptake enhancer (SSRE). Unlike conventional tricyclic antidepressants, tianeptine enhances the reuptake of serotonin instead of inhibiting it, opposite to the action of SSRIs. Tianeptine, indicated as a thymoleptic, antagonises the effects of serotonin in the limbic system and the pre-frontal cortex, giving rise to a mood elevation, unlike the mood blunting associated with SSRIs.

Its short-lived, but pleasant, stimulant effect experienced by some patients is shared with its predecessor, amineptine, whose side effects related to dopamine uptake inhibitor activity resulted in Servier's research into Tianeptine. Suggested dosage is three times daily, due to its short duration of action. Tianeptine is synergistic and has been used in conjunction with other drugs such as modafinil.

Tianeptine is claimed to have strong antidepressant and anxiolytic properties with a relative lack of sedative, anticholinergic and cardiovascular adverse effects, thus suggesting it is particularly suitable for use in elderly patients and in those following alcohol withdrawal; such patients can be more sensitive to the adverse effects of psychotropic drugs.

Currently, tianeptine is approved in France and manufactured and marketed by Laboratoires Servier SA; it is also marketed in a number of other European countries under the trade name Coaxil as well as in Asia and Latin America as Tatinol. The last remaining production (in Latin America) for its predecessor amineptine was discontinued in 2006, leaving tianeptine as the sole antidepressant in Servier's portfolio.